Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The Company has pioneered the development of a rapid injection, anti-toxin antibody, Anthim®, for the prophylaxis and treatment of anthrax disease following a biowarfare attack. Anthim has consistently demonstrated significant efficacy in multiple non-clinical animal studies and has been successfully evaluated in three clinical safety trials.
In December 2009, Elusys received an advanced development contract totaling to $143 Million from the Biomedical Advance Research and Development Authority of Health and Human Services to complete final development for procurement of Anthim into Strategic National Stockpile and submission of a BLA application for FDA licensure.
Elusys's success in the development of Anthim has been achieved by our talented team of scientists, project managers and business professionals who are committed to making Anthim available for the protection of Americans.